BGNE (BeiGene, Ltd.) Forward P/E Multiple

Official company branding of BeiGene (BGNE)

The implementation of automated bio-screening systems accelerates drug discovery, which impacts the expected price-to-earnings multiple of BeiGene, Ltd. (BGNE). The value of 39.60 captures the magnitude of this parameter. Aggressive market expansion and patent protection are critical in the struggle against global behemoths. Meanwhile, strategic alliances with Western leaders create synergy, stimulating mergers and acquisitions within the structure of BeiGene, Ltd. (BGNE).

BeiGene - BGNE Forward P/E Multiple (period 07/04/2022 - 11/16/2026)

Summary analytical data breakdowns for BeiGene, Ltd. (BGNE)

- current price and projected stock value:
General company analysis:beigene.com
Brand item of BeiGene Ltd

For BeiGene, Ltd., which monetizes a patent-protected portfolio of oncology drugs, the company's forward P/E ratio serves as an indicator of the market valuation of future cash flows. This metric compares the current market value of the business with projected net income, allowing investors to identify whether the asset is overbought or possesses growth potential amid expanding global sales through an analysis of the chart.

Competitors of BeiGene, Ltd. (BGNE)

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TuHURA (HURA) - Forward P/E Multiple|TARA (Protara Therapeutics Inc) - Forward P/E Multiple|FATE: Future Price to Earnings Multiple|Forward P/E Multiple WHWK|TCRX (TScan) - Future Price to Earnings Multiple|Future Price to Earnings Champions Oncology, Inc. CSBR|XBIT - Projected Price to Earnings|CEL-SCI - Forward P/E Multiple|OSTX - Forward P/E Multiple|Radiopharm Theranostics Limited (RADX) - Future Price to Earnings|ARTV - Market Cap to Projected Earnings|Projected Price to Earnings ANL|Future Price to Earnings VERU|Forward P/E Multiple TPST|XLO: Price to Expected Earnings Ratio|Forward P/E Multiple RENB (Renovaro Inc.)|Mural Bio (MURA) - Projected Price to Earnings Ratio|Kairos Pharma Ltd - Forward P/E Multiple|Price to Expected Earnings Ratio OKUR|CytoMed Therapeutics Limited (GDTC) - Future Price to Earnings|CRIS - Market Cap to Projected Earnings|Projected Price to Earnings APLM|Tharimmune (THAR) - Market Cap to Projected Earnings|Projected Price to Earnings ADVB (Advanced Biomed Inc.)|Genprex - Price to Future Earnings Ratio|Forward P/E Multiple CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Projected Price to Earnings|Xenetic Bio - Forward P/E Multiple|SLRX - Forward P/E Multiple|PPBT: Forward P/E Multiple|Price to Future Earnings Ratio AONC|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple